Market capitalization | $444.91m |
Enterprise Value | $432.20m |
P/E (TTM) P/E ratio | 29.88 |
EV/FCF (TTM) EV/FCF | 23.89 |
EV/Sales (TTM) EV/Sales | 7.33 |
P/S ratio (TTM) P/S ratio | 7.55 |
P/B ratio (TTM) P/B ratio | 5.11 |
Revenue growth (TTM) Revenue growth | -11.93% |
Revenue (TTM) Revenue | $58.94m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Semler Scientific:
1 Analyst has issued a forecast Semler Scientific:
Sep '24 |
+/-
%
|
||
Revenue | 59 59 |
12%
12%
|
|
Gross Profit | 52 52 |
16%
16%
|
|
EBITDA | 21 21 |
16%
16%
|
EBIT (Operating Income) EBIT | 20 20 |
16%
16%
|
Net Profit | 16 16 |
19%
19%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluate its customers patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler and Shirley L. Semler on August 9, 2007 and is headquartered in Santa Clara, CA.
Head office | United States |
CEO | Douglas Murphy-Chutorian |
Employees | 92 |
Founded | 2007 |
Website | www.semlerscientific.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.